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Purpose: To prepare and evaluate spherical agglomerates of pioglitazone hydrochloride (PGH) for 
direct compression with different additives. 
Method: Spherical agglomerates of pioglitazone hydrochloride were prepared by emulsion solvent 
diffusion method with and without additives (polyethylene glycol 6000, polyvinyl pyrrolidone, β 
cyclodextrin, Eudragit RS100, low acyl gellan gum and xanthan gum) using methanol, chloroform and 
water as good solvent, bridging liquid and poor solvent respectively. The agglomerates were evaluated 
for compressibility, solubility and dissolution rate and also by scanning electron microscopy (SEM), X-
ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and fourier transforms infrared 
spectroscopy (FTIR). 
Results: The particle size, flowability, compactibility, packability, solubility and dissolution rate of plain 
agglomerates and agglomerates with additives, except polyvinyl pyrrolidone, were enhanced compared 
with the original crystals of pioglitazone hydrochloride. This might be attributed to their large size (10 x 
original PGH crystals), spherical shape, enhanced fragmentation during compaction (yield pressure 
increased from 22.6 to 29.3 MPa) and reduced elastic recovery of compacts (from 8.1 to 5.5 %) 
compared to the original drug crystals.  XRPD and DSC studies indicate polymorphic transition of PGH 
in all agglomerates from form II to I during recrystallization; FTIR spectra show that this was not 
associated with any chemical transition. 
Conclusion: The findings indicate that spherical crystallization by emulsion solvent diffusion method to 
produce agglomerates containing selected additives is a satisfactory approach for the formulation of 
directly compressed pioglitazone hydrochloride tablets. 
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INTRODUCTION 
 
Direct tabletting is an efficient process 
involving mixing and compression of powders 
to save time and cost, compared with granule 
tabletting [1]. However, it strongly depends 
on the flowability, compactibility and 
packability of the drug crystals used; 
otherwise considerable amounts of excipients 
are necessary, resulting in oversized tablets. 
Crystals could be generated by employing 
any of the available techniques such as 
sublimation, solvent evaporation, vapor 
diffusion, thermal treatment, crystallization 
from melt precipitation and growth in the 
presence of additives [2]. Fine crystals are 
preferred to large crystals of poorly soluble 
pharmaceuticals as they provide greater 
bioavailability. However, micronization of 
crystals frequently prevents efficient powder 
processing due to poor flowability, 
compactibility and packability [3].  
 
Thus, novel agglomeration technique that 
transforms crystals themselves directly into a 
compacted spherical form during 
recrystallization process has been desired. 
The use of spherical crystallization technique 
appears to be an efficient alternative for 
obtaining suitable particles for direct 
compression [4]. Spherical crystallization is a 
particle design technique whereby 
recrystallization and agglomeration are 
carried out simultaneously in one step and 
has been successfully utilized for 
improvement of flowability and compactibility 
of crystalline drugs [5]. Various methods are 
reported in the literature for generating 
spherical agglomerates, including spherical 
agglomeration (SA), emulsion solvent 
diffusion (ESD), ammonia diffusion and 
neutralization [6]. Among these, SA and ESD 
methods are widely employed [7,8].  
 
Pioglitazone hydrochloride (PGH) is 
thiazolidinedione oral antidiabetic used in the 
management of type II diabetes mellitus. It is 
rapidly absorbed after oral administration; 
peak plasma concentrations are obtained 
within two hours [9].  
 
The aim of the present investigation was to 
study the effect of some additives - 
polyethylene glycol 6000, polyvinyl 
pyrrolidone, β cyclodextrin, eudragit RS100, 
low acyl gellan gum and xanthan gum - on 
micromeritic properties, flowability, 
compactibility, packability, solubility and drug 
release of PGH agglomerates prepared using 






Pioglitazone hydrochloride (PGH) and β 
cyclodextrin (β-CD) were kindly provided by 
Alembic Research Centre, Gujarat, India. 
Low acyl gellan gum (GG) and xanthan gum 
(XG) were provided by C.P. Kelco Pvt. Ltd. 
Mumbai (India) free of charge. Eudragit RS 
100 (EU), polyethylene glycol 6000 (PEG), 
polyvinyl pyrrolidone (PVP), methanol and 
chloroform were purchased from Rajesh 
Chemicals, Pune, India. All chemical used 
were of analytical grade.  
 
Preparation of spherical agglomerated 
PGH crystals  
 
PGH (10 g) was dissolved in a mixture of 60 
ml methanol (good solvent) and 40 ml 
chloroform (bridging liquid). The resultant 
solution was poured into 500 ml of distilled 
water (poor solvent) containing 1 %w/v of 
either PEG, PVP, β-CD, EU, GG or XG, with 
stirring at 800 rpm for 20 min at 25 °C. The 
recrystallized agglomerates obtained were 
collected by vaccum filtration and dried in an 
oven at 60 °C for 4 h and stored in a 
desiccator at room temperature before use. 
The process was repeated several times for 
each formulation type to obtain enough for 
characterization and to assess repeatability. 
 
Determination of yield and drug content 
 
The yield (total dry weight) of the 
agglomerates was determined by weighing 
the agglomerates after drying. For 
determination of drug content, spherical 
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agglomerates of PGH equivalent to 100 mg 
of PGH were triturated and dissolved in a 
solvent system consisting of methanol: water: 
concentrated hydrochloric acid in a 250:250:1 
(ml) ratio. Appropriately diluted samples were 
filtered through Whatman filter paper no. 
41(pore size 25 µm) and drug content 
determined spectrophotometrically at 269 nm 
(model V530, Jasco, Japan).  
 
Micrometric properties of raw crystals and 
spherical agglomerates 
 
The mean particle size of PGH and its 
agglomerates was determined by measuring 
the average diameter of 100 particles 
(randomly selected) with an optical 
microscope (model GEM 2121, Gaurav 
Enterprises, India), Their SEM micrographs 
were taken (model S120, Cambridge, United 
Kingdom).  Bulk density and tap density was 
determined as follows. A 50 ml glass cylinder 
was weighed and filled with 30 g sample. The 
opening was securely sealed with parafilm. 
The cylinder was gently inverted once and 
the powder was carefully leveled without 
compacting. Bulk volume was determined 
after one mechanical tap and tap volume was 
measured after 2000 taps on a tap density 
tester (model T2, Dolphin, India). Bulk 
density, tap density, Carr’s index, Hausners 
ratio and angle of repose by fixed funnel 
method were determined as in Eqs 1 – 3 [10]. 
Carr’s index= [(Tap density- Bulk 
density)/Tap density] X 100 ………….  (1) 
 
Hausners ratio= Tap density/Bulk density..…(2) 
Angle of repose = tan
-1
 (height of pile/radius 




The solubility of the plain crystals and 
spherical agglomerates of PGH were 
determined in both distilled water and pH 2 
potassium chloride (KCl) buffer. Excess 
amount of sample were added to 20 ml of 
distilled water or KCl buffer, continuously 
shaken (300 rpm) at 25 ± 0.5 °C for 48 h and 
sonicated using a sonicator (model T-SONIC, 
Dolphin, India) for 2 h. The samples were 
filtered through a 0.45 µm filter and assayed 
spectrophotometrically for drug content at 
269 nm. 
 
Compaction behavior of raw crystals and 
spherical agglomerates 
 
Heckel study [11] was performed by 
compressing 500 mg of raw crystals or 
spherical agglomerates on a hydraulic press 
(Samrudhi Enterprises, Mumbai, India.) using 
13 mm flat-faced punch and die set at 
pressures of 20, 30, 40, 60, 80, 100 and 120 
kN. The thickness, weight and diameter of 
the compacts were determined. Heckel 
parameters were determined using Heckel 
equation (Eq 4). Also, the elastic recovery 
(ER), thickness of the compact of 
agglomerates and raw crystal of PGH were 
determined at a compression pressure 60 kN 
and at 24 h after releasing the tablet from the 
die [12]. 
 
ln (1/1-D) = KP + A ..…………………….. (4) 
 
where D is the relative density of powder for 
applied pressure P. The slope of the straight-
line portion, K, is the reciprocal of the mean 
yield pressure (MYP) of the material. 
                                                 
Packability determination 
 
In packability determination, 25 g of the 
sample was poured slowly and gently into a 
25 ml measuring cylinder and tapped for 100, 
200, 300, 400, 500, 600, 700, 800, 1100 and 
1200 times using a Stampfvolumeter. 
Compactibility and cohesiveness values were 
calculated using the modified Kawakita and 
Kuno equations, respectively (Eqs 5 and 6)  
[13,14]. 
 
(n/C) = (1/ab) + (n/a) …………………. (5) 
 
where, C = (Vo – Vn)/Vo, a = (Vo – V∞)/Vo, n = 
number of taps, C = difference in volume 
(degree of volume reduction), a and b = 
constant for packability and flowability, 
respectively, Vo = initial volume, Vn = final 
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volume after n
th
 tap, and V∞ = powder bed 
volume at equilibrium. 
 
ρf – ρn = (ρf – ρo) e
–kn
 ………………… (6) 
 
The value of k in Kuno’s equation was 
determined directly incorporating the density 
values in Eq 6, where, ρf, ρo and ρn are 
apparent densities at equilibrium, initial state 
and after n
th
 tap, respectively.  
 
Scanning electron microscopy (SEM) 
 
Agglomerates were coated with a thin gold-
palladium layer with a sputter coater unit 
(VG- Microtech, United Kingdom), and the 
surface topography was analyzed with a 
Cambridge Stereoscan scanning electron 
microscope (S120; Cambridge, United 
Kingdom) operated at an acceleration voltage 
of 10 kV. 
 
X-ray powder diffraction (XRPD) 
 
X-ray powder diffraction of raw crystals and 
spherical agglomerates were analyzed by 
Philips PW 1729 x-ray diffractometer. 
Samples were irradiated with 
monochromatized Cu Kα –radiations (1.542 
A°) and analyzed between 2 - 60° (2θ). The 
voltage and current used were 30kV and 30 
mA, respectively. The range was 5 x 10
3 
cycles/s and the chart speed was kept at 100 
mm/2θ. 
 
Differential scanning calorimetry (DSC) 
 
The thermal properties of the raw crystals 
and spherical agglomerates of PGH were 
analyzed by DSC (TA Instruments, USA, 
Model: SDT 2960). Indium standard was 
used to calibrate the DSC temperature and 
enthalpy scale while nitrogen was used as 
the purge gas at a flow rate of 50 ml per min 
through the DSC cell and 100 ml per min 
through the cooling unit. The sample (5 – 10 
mg) was heated in a hermetically sealed 
(without perforation) aluminum pans. Heat 
run was set from 0 to 300 °C at a heating rate 
of 10 °C/min. 
Fourier transform infrared spectroscopy 
(FTIR) 
 
Fourier transform infrared spectroscopy of 
the raw crystals and spherical agglomerates 
of PGH was recorded using a model V5300 
(Jasco, Japan) FTIR system using potassium 
bromide (KBr) pellet. Each spectrum was 
derived from single average scans collected 




In-vitro dissolution studies 
 
Dissolution studies on the raw crystals and 
spherical agglomerates of PGH (equivalent to 
100 mg of PGH) were performed using a 
USP 26 type II dissolution test apparatus 
(Dolphin
TM
, Mumbai, India) in 900 ml of pH 2 
KCl buffer at 37 ± 2°C and 100 rpm stirring. 
Samples were collected periodically and 
replaced with equivalent volume of fresh 
dissolution medium. After filtration through 
Whatman filter paper 41(pore size: 25 µm), 
the concentration of PGH was determined 




The results obtained are expressed as mean 
± standard deviation (SD) ofr triplicate 
measurements. The results were statistically 
analyzed and significant differences 
determined by one-way analysis of variance 
(ANOVA) using ‘Graph Pad Instat
®
’Version 
3.05 (USA) program. Statistically significant 




Spherically agglomerated crystals of PGH 
 
In the absence of a bridging liquid, the 
system produced agglomerates rich in 
needle-shaped crystals. At optimized 
concentration of good solvent and bridging 
liquid (3:2), the optimum rate was 800 rpm. 
Formation of lumps and agglomerates of un-
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uniform size and shape was observed at 
lower stirring rates, while high stirring rate 
destroyed the agglomerates. Yield and drug 
content of the PGH agglomerates were 
satisfactory, as shown in Table 1. 
 
Micrometric properties of agglomerates 
 
The micromeritic properties of the 
agglomerates are given in Table 1. The 
particle size of plain agglomerates (i.e., 
without additive) and agglomerates with 
additives (except PVP) increased by more 
than 10 times compared to the original 
crystals. This may be due to particle 
aggregation. SEM (figure 1) of drug, plain 
agglomerates and agglomerates with 
additives reveals that the agglomerates were 
spherical and had a smooth surface. The bulk 
densities of the plain agglomerates and 
agglomerates with additives (except PVP) 
was lower than those of the original crystals 
of PGH. Furthermore, the angle of repose, 
Carr’s index and Hausner ratio values of the 
plain agglomerates and agglomerates with 
additives (except PVP) were lower than those 
of the original crystals of PGH. 
 
 
Compaction behavior of agglomerates
 
 
Heckle parameter MYP and ER for the 
original crystals and agglomerates of PGH 
are given in Table 2. The elastic recoveries of 
the compacts of plain agglomerates and 
agglomerates with PEG, β-CD, EU, GG and 





The packability parameters (a, b and k) 
obtained from Kawakita and Kuno equations, 
respectively, are given in Table 3. For plain 
agglomerates and agglomerates with PEG, β-
CD, EU, GG and XH, the value of parameter 
a in Kawakita equation decreased while 
parameters b and k in Kawakita and Kuno 
equations, respectively, increased compared 
with those of the original crystals of PGH and 




The solubility data are given in Table 3. It 
was observed that solubility of spherical 
agglomerates was higher than that of the 
original PGH crystals. Solubility was highest 
for β-CD agglomerates and lower for PVP 
agglomerates. 
 
X-ray powder diffraction (XRPD) 
 
PGH has at least two polymorphic forms, 
namely, forms I and II. Diagnostic peaks for 
form I are at 2θ= 8.7, 12.7, 18.8, 20, 20.1, 
22.7, 26.6, 28.3 and for form II, they are at 2θ 
= 9.2, 10.4, 15.2, 16.4, 18.6, 21.4 [15].  
XRPD diffractograms show in Figure 2(I) 
indicate that PGH crystals were form II but 
changed to form I in the agglomerates. 
 
Table 1: Micrometric properties of original crystals and agglomerates of PGH  
 























Original crystals  - - 16.7±1.1 52.2±0.7 0.32±0.01 32.3±0.5 1.42±0.04 
Plain agglomerate  96±2 92±2 162.3±1.1 23.1±0.6 0.21±0.01 15.0±0.4 1.18±0.05 
Agglomerate with PEG 95±1 94±1 151.5±0.8 22.2±0.7 0.28±0.01 14.1±0.6 1.16±0.04 
Agglomerate with β-CD 97±1 91±3 158.7±1.2 23.2±0.2 0.27±0.01 14.1±0.7 1.16±0.05 
Agglomerate with EU 95±2 92±2 146.5±0.7 24.1±0.3 0.27±0.00 15.0±0.5 1.17±0.06 
Agglomerate with GG 94±2 93±1 149.5±0.8 26.1±1.1 0.28±0.01 14.3±0.7 1.16±0.09 
Agglomerate with XG 97±1 91±2 152.5±0.5 21.2±0.9 0.27±0.01 18.7±1.1 1.23±0.03 
Agglomerate with PVP 92±3 90±2 18.4±1.0 39.2±0.4 0.33±0.00 31.2±0.5 1.45±0.03 
(DC: Drug content, PEG: polyethylene glycol 6000, β-CD: β- cyclodextrin, EU: eudragit RS 100, GG: low 
acyl gellan gum, XG: xanthan gum, PVP: polyvinyl pyrrolidone) 
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Figure 1: SEM micrographs of PGH crystals (A-1, 
A-2); plain agglomerates (B-1, B-2); agglomerates 
prepared with polyethylene glycol (C-1, C-2); 
agglomerates prepared with β- cyclodextrin (D-1, 
D2); agglomerates prepared with polyvinyl 
pyrrolidon (E-1, E-2). Note: Post-fix ‘1’ and ‘2’ in 
the codes denote low and high magnifications, 
respective 
 
Differential scanning calorimetry (DSC) 
 
PGH crystals showed a melting endotherm at 
192.6 °C with heat of fusion of  -120 J/g while 
all the agglomerates of PGH showed a 
melting endotherm at 182 °C with heat of 
fusion -99.24 J/g, as shown in Figure 2(II). 
 
Table 2: Heckel-derived parameters, namely, 
MYP (mean yield pressure) and ER (elastic 
recovery) of PGH crystals and agglomerates (n = 
3)  
 
PGH type MYP (MPa) % ER 
Crystals  22.5± 2.4 8.1 ± 1.2 
Agglomerate (plain)  27.4± 1.8 ** 4.8 ± 0.4 *** 
Agglomerate with 
PEG 
25.3± 1.6 ** 5.1 ± 0.6 *** 
Agglomerate with β-
CD 
28.3± 2.3 ** 5.0 ± 0.5 *** 
Agglomerate with 
EU 
26.3± 1.5 ** 5.8 ± 0.7 *** 
Agglomerate with 
GG 
29.3± 1.2 ** 6.1 ± 0.8 *** 
Agglomerate with 
XG 
26.3± 1.7 ** 5.5 ± 0.4 *** 
Agglomerates with 
PVP 
21.3± 2.9 * 7.8 ± 0.8 * 
*** p < 0.001; ** p < 0.01; ;* p < 0.05,  compared with 
PGH crystals. Note: PEG = polyethylene glycol 6000, β-
CD = β-cyclodextrin, EU = Eudragit RS 100, GG = low 
acyl gellan gum, XG = xanthan gum, PVP = polyvinyl 
pyrrolidone 
 
Fourier transforms infrared spectroscopy 
(FTIR) 
 
Fig 2(III) shows that the FTIR spectrum of 
PGH original crystals  displayed absorption 
bands at 3358, 2928, 2854, 1741, 1705, 
1610, 1516, 1460, 1383, 1333, 1254, 1180, 
1159, 1040, 1012, 824, 719, 658, 598, 563, 
542, 521 cm
-1
. The characteristic absorption 
peaks of PGH are 3358 for N-H stretching, 
2928 and 2855 for C-H stretching in CH2 
group, 1742 and 1705 for asymmetric C=O 
stretching, 1610 and 1516 for C=C stretching, 
1460 for CH2 deformation, 1383 for 
asymmetric CH3 deformation, 1333 mixed 
vibration, 1254 for C-H bending, 1181 for C-O 
stretching, 1159 for CH2 wagging, 1044 for C-
H bending, 1017 for CH2 scissoring, 720 for 
CH2 rocking, 658 and 598 for ring 
deformation, 563 for C=O bending, 542 for N-
H bending, and 521 for C-C bending in 
benzene ring. Thus PGH crystals and spheri- 
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) and Kuno’s constant k (10
-4
) and solubility data for original 
crystals and agglomerates of PGH. (n=3)  
 
Solubility (µg/ml) 
PGH type a b k 
Water KCl buffer pH 2 
Crystals 43±0.06 30.4±0.005 25.8±0.001 30±1.2 109±2.3 
Agglomerate (plain) 27.4±0.05 25.5±0.003 10.8±0.006 76±1.6 *** 227±3.1 *** 
Agglomerate with PEG 28.8±0.06 11.8±0.004 10.2±0.004 82±2.1 *** 268±2.1 *** 
Agglomerate with β-CD 28.8±0.03 10.4±0.006 10.5±0.006 98±1.8 *** 408 ±4.3 *** 
Agglomerate with EU 27.8±0.02 21. ±0.003 11.0±0.003 78±1.1 *** 248±3.2 *** 
Agglomerate with GG 28.1±0.04 19.5±0.006 10.7±0.007 68±2.2 *** 238±2.6 *** 
Agglomerate with XG 29.6±0.03 31.6±0.009 11.8±0.008 71±1.9 *** 255±2.9 *** 
Agglomerate with PVP 43.5±0.07 31.3±0.006 26.2±0.003 49±1.4 ** 136 ±1.6 ** 
*** p < 0.001; ** p < 0.01; ;* p < 0.05,  compared with PGH crystals. Note: PEG = polyethylene glycol 6000, β-CD = β-





Figure 2: XRPD spectra (I), DSC thermograms (II) 
and FTIR spectra (III) of PGH crystals (A); plain 
agglomerates (B); agglomerates prepared with 
polyethylene glycol 6000 (C),;agglomerates 
prepared with β- cyclodextrin (D); agglomerates 
prepared with Eudragit RS 100 (E); agglomerates 
prepared with low acyl gellan gum (F); 
agglomerates prepared with xanthan gum (G); and 
agglomerates prepared with polyvinyl pyrrolidone 
(H) 
 
cal   agglomerates   of  PGH  exhibited 
identical IR spectra [16].    
 
In-vitro drug release  
 
As shown in Figure 3 for PGH crystals, 
approximately 67 % of the drug was released 
in 30 min while for the agglomerates, drug 
release within the same period was > 95 % 
except for  the agglomerate with PVP  which 
exhibited 85 %  drug release. Increase in 
drug release was in the order: β-CD > PEG > 






When the solution of drug in good solvent 
and bridging liquid was poured into the poor 
solvent, quasi-emulsion droplets of the drug 
solution were produced initially. 
Subsequently, crystallization of the drug 
occurred at the outer surface of the droplet. 
The spherically agglomerated crystals were 
produced simultaneously after complete 
crystallization and hence the whole process 
is known as emulsion solvent diffusion [6]. 
Under stirring, the agglomerates were 
spheronized and compacted. 
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Figure 3: Drug release profile of, PGH crystals (∆) 
plain agglomerates (♦),agglomerates prepared 
with polyethylene glycol 6000 (▲), agglomerates 
prepared with β- cyclodextrin (○), agglomerates 
prepared with Eudragit RS 100 (◊),agglomerates 
prepared with xanthan gum (●), agglomerates 
prepared with low acyl gellan gum (■); and 
agglomerates prepared with polyvinyl pyrrolidone 
(□). 
 
Micrometric properties  
 
Reduction in the bulk densities of the 
agglomerates indicates the greater porosity 
within the agglomerates [17]. PVP most 
effectively decreased the mean diameter of 
the agglomerates probably due to its 
adsorption on the surface of the crystals thus 
hindering crystal aggregation. The angle of 
repose, Carr’s index and Hausners ratio 
values of the agglomerate with PVP indicate 
poor flowability. In case of agglomerates with 
PEG, β-CD, EU, GG and XG average 
diameter was higher than for the original 
crystals but lower than for plain 
agglomerates. These findings suggest that 
these additives were poorly adsorbed at the 
surface which would reduce interfacial 
tension between bridging liquid and crystals, 
with a consequent decrease in the adhesive 







The compressibility of a material is its ability 
to reduce in volume as a result of an applied 
pressure [10]. Db value represents the 
particle rearrangement phase in early 
compression stage and tends to indicate the 
extent of particle fragmentation. Higher Db 
values indicated that the agglomerates were 
highly fractured during the early stage of 
compression although fragmentation is 
followed by plastic deformation. The results 
were well supported by higher yield pressure 
(MYP) values. The improved compactibility of 
agglomerates might be attributed to a 
characteristic structure responsible for the 
large relative volume changes during the 
early stage of the compression process due 
to their fragmentation. Elastic recovery 
studies have suggested that agglomerated 
crystals are easily fractured, and the new 
surface of crystals produced might contribute 
to promote plastic deformation under 
compression [19]. The lower Db value of the 
agglomerate with PVP compared to the other 





The packability of plain agglomerates and 
agglomerates with PEG and β-CD were 
improved as a results of agglomeration, thus 
making them suitable for for direct 
compression tabletting. During tabletting, 
these agglomerates should flow smoothly 
from the hopper into die cavity to attain the 
uniformity in weight necessary in direct 
tabletting. The improvement in packability 
and flowability is attributable to size 
enlargement and the spherical shape of the 
agglomerates [17].  
 
Solubility and in-vitro drug release  
 
Increase in solubility and dissolution rate of 
agglomerates of PGH may be attributed to 
increase in wettability and porosity brought 
about by the additives. The contrary results 
for PVP agglomerates is probably due to the 
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possibility that hardly any agglomeration 
occurred when PVP was used as an additive. 
 
X-ray powder diffraction (XRPD) 
 
XRPD of the original crystals of PGH indicate 
form II and those of the agglomerates 
corresponded to form I [15], thus 
demonstrating that during crystallization of 
PGH, there was polymorphic transition of 
PGH from form II to form I. The evidence is 
the absence of peaks at 8.7, 20, 22.7 and 
26.6 in the agglomerates of PGH. 
 
Differential scanning calorimetry (DSC): 
 
DSC is generally combined with XRPD to 
determine polymorphic composition of 
pharmaceutical powders when polymorphs 
present different melting points. The DSC 
study confirms that the original PGH crystals 
is form II and it was changed to form I during 
agglomeration and recrystallization [15].  
 
Fourier transforms Infrared spectroscopy 
 
The FTIR study clarifies that the altered 
XRPD spectra and DSC thermograms of the 
drug and its agglomerates were not 
associated with any changes at the molecular 
level [16]. It revealed that no chemical 





Spherical agglomerates of PGH were 
successfully prepared by emulsion solvent 
diffusion method. Flowability, compactibility, 
packability, solubility and dissolution were 
greatly improved for all the agglomerate 
types of PGH, except with PVP. During 
agglomeration polymorphic transition 
occurred but this was not associated with 
changes at molecular level. Spherical 
crystallization of PGH with selective additives 
is a satisfactory method for direct tabletting of 
PGH. However, scale-up would be required 
to determine if the method can be used for 
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